Santhi Ganji

发表

Scheme 3, General synthetic strategy for analogs of ML261

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Table 4, Probe and Analog Submissions to MLSMR (BioFocus DPI) for Gli-Sufu Antagonist ML340

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Figure 9, Structure of confirmed most attractive screening hits

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 7, Hit triage for Lipid Droplets

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Scheme 1, Synthesis of ML307, conditions

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Table 4, Probe and Analog Submissions to MLSMR (BioFocus DPI) for UBC13 Inhibitors

Santhi Ganji, Ian Pass, Robert Ardecky, 2013 .

Table 3, CID 56639556 [ML307] MLS-0471611

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Scheme 1, Synthesis of ML261, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Scheme 1, Synthesis of ML260

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Figure 10, SAR strategy for Scaffold I

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 5, Screening results and Hit validation

John C. Reed, Santhi Ganji, Ian Pass, 2011 .

Table 5, Potencies of key screening hit scaffolds

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Scheme 2, Synthesis of ML262, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .